HAVCR2 and myeloid leukemia: The individual mechanistic contributions to the eradication of TIM-3+ leukemic cells and blasts, as reflected in the promising clinical activity observed in a phase 1 trial of sabatolimab in patients with myeloid leukemias [41], remains a focus of future studies.